In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Importance More than 40 million people are living with either mitral or aortic valve disease
worldwide, and more than 180 000 heart valve replacement surgeries are performed each …

Objectives: The aim of this study was to compare aspirin plus clopidogrel with aspirin alone
as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the …

Background: There are limited data on the incidence, clinical implications, and predisposing
factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve …

Background: The incidence and prognostic impact of late bleeding complications after
transcatheter aortic valve replacement (TAVR) are unknown. Objectives: The aim of this …

Background—Early stent valve thrombosis after transcatheter aortic valve implantation
(TAVI) is a rare complication, which is diagnosed based on the appearance of clinical …

Aims A comprehensive description of transcatheter heart valve (THV) failure has not been
performed. We undertook a systematic review to investigate the aetiology, diagnosis …

Background Antithrombotic treatment regimen following transcatheter aortic valve
replacement (TAVR) is not evidence-based. Apixaban, a non-vitamin K direct anticoagulant …

Objectives: The aims of this study were to assess the epidemiology of atrial fibrillation (AF) in
patients treated with transcatheter aortic valve replacement (TAVR) and included in the large …

Background—Prior studies of stroke and transient ischemic attack (TIA) after transcatheter
aortic valve replacement (TAVR) are limited by reporting and follow-up variability. This is a …